The non-cancer bispecific pipeline: Data Byte

Use of bispecific technologies is creeping beyond cancer, where the approach now underpins 130-plus clinical programs. Collectively, companies have advanced 19 bispecific candidates into human trials across the four disease areas, hematology, ophthalmology, autoimmune and infectious diseases, according to BioCentury’s BCIQ database.

The sole bispecific that’s marketed for a non-cancer indication is hemophilia therapy Hemlibra emicizumab-kxwh from  Roche (SIX:ROG; OTCQX:RHHBY) and Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), and two other bispecifics are coming up behind Hemlibra in the indication: Mim8 from Genmab A/S (CSE:GMAB; NASDAQ:GMAB) and next-generation candidate NTX007 from Chugai...